Biotechs are becoming increasingly cautious about what they publish in scientific journals. The growing worry is that other companies, often based in China, will take the freshly published information and run with it – and go on to develop a target or very early stage drug much faster than the originator. This was a subject raised last week on a panel at the Anglonordic Life Science Conference in London, by Dr Adi Hoess, CEO […]
A profoundly positive response from Anglonordic attendees with hands shaken, conversations started and potential deals in the works. The main takeaway was the benefit of it being a ‘boutique’ event, meaning everyone could make the most of the 1:1 partnering, pitch presentations, and networking breaks. Keep reading to hear more about what’s been happening this […]
I spent 20 years as a print journalist and my first love will always be the written word. But you might have noticed we’ve switched our Hot Topic articles from being a purely written affair, to something that we deliver primarily by video. There’s a very simple reason for this. Video gets more views. Way […]
R1 Therapeutics launches with oversubscribed $77.5 million Series A financing to advance first-in-class treatment for hyperphosphatemia in patients with chronic kidney disease R1 Therapeutics, Inc, a clinical-stage biopharmaceutical company focused on the development of first-in-class therapies for patients with kidney disease, announced its launch with an oversubscribed $77.5 million Series A financing, along with the […]
Novo Nordisk Foundation grants DKK 5.5 billion to elevate innovation in Denmark and Europe The Novo Nordisk Foundation has allocated up to DKK 5.5 billion (EUR 736 million) to the BioInnovation Institute (BII), a leading institute for life science and deep tech innovation in Copenhagen. The funding will enable BII to expand its activities into […]
